Senseonics (NYSE:SENS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report report published on Friday morning. The firm issued a sell rating on the stock.

Senseonics Price Performance

NYSE SENS opened at $0.51 on Friday. The company has a 50 day simple moving average of $0.53. Senseonics has a 12-month low of $0.38 and a 12-month high of $1.05. The company has a debt-to-equity ratio of 1.15, a quick ratio of 7.03 and a current ratio of 7.53.

Senseonics (NYSE:SENS) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Senseonics had a negative net margin of 270.13% and a negative return on equity of 146.90%. The business had revenue of $8.00 million during the quarter, compared to analysts’ expectations of $7.62 million. On average, equities analysts expect that Senseonics will post -0.13 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Cornerstone Wealth Management LLC increased its stake in Senseonics by 55.9% during the 3rd quarter. Cornerstone Wealth Management LLC now owns 55,750 shares of the company’s stock valued at $34,000 after purchasing an additional 20,000 shares in the last quarter. RPO LLC bought a new stake in Senseonics during the 4th quarter valued at about $37,000. Ausdal Financial Partners Inc. boosted its holdings in shares of Senseonics by 53.2% during the 3rd quarter. Ausdal Financial Partners Inc. now owns 72,000 shares of the company’s stock valued at $43,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after acquiring an additional 211,128 shares during the last quarter. 12.36% of the stock is currently owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.